Stay updated with breaking news from Nasdaq mltx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Federated Hermes Inc. lessened its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 2.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,060,526 shares of the company’s stock after selling 23,724 shares during the quarter. Federated Hermes Inc.’s holdings […] ....
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 116.54% from the […] ....
The Goldman Sachs Group began coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report released on Tuesday morning, MarketBeat reports. The firm issued a neutral rating and a $62.00 target price on the stock. A number of other equities analysts have also recently weighed in on MLTX. HC Wainwright reissued […] ....
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokers […] ....
Polar Capital Holdings Plc lessened its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 41.9% during the third quarter, HoldingsChannel.com reports. The firm owned 939,012 shares of the company’s stock after selling 676,377 shares during the period. Polar Capital Holdings Plc’s holdings in MoonLake Immunotherapeutics were worth $53,524,000 as of its most recent SEC […] ....